We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Colgate (CL) Q2 Earnings In Line, Sales Miss, Stock Down
Read MoreHide Full Article
Colgate-Palmolive Company (CL - Free Report) , a global dealer in consumer goods, came out with second-quarter 2018 results. It recorded adjusted earnings of 77 cents per share, which came in line with the Zacks Consensus Estimate but grew 7% year over year.
For 2018, management envisions adjusted earnings per share to grow in mid-single-digit range on a year-over-year basis. However, GAAP earnings per share are expected to rise at double-digit rate.
Earnings Estimate Revision: The Zacks Consensus Estimate for 2018 has witnessed a downtrend in the last seven days. However, if we look at Colgate’s performance in the trailing four quarters (excluding the quarter under review), the company has outperformed the Zacks Consensus Estimate by an average of 0.3%.
Colgate-Palmolive Company Price, Consensus and EPS Surprise
Revenues: Colgate’s sales increased 1.5% to $3,886 million during the quarter, owing to 1.5% growth from volumes and 4.5%. Pricing remained flat with the prior-year period. Organic sales rose 0.5% in the quarter. However, sales came below the Zacks Consensus Estimate of $3,899 million.
Depending upon the current spot rates, management anticipates both net sales and organic sales to grow in low-single digits in 2018.
Zacks Rank: Currently, Colgate carries a Zacks Rank #4 (Sell), which is subject to change, based on the just released earnings results.
Stock Movement: Colgate’s shares dipped nearly 3.6% during pre-market trading hours following the earnings release.
Check back later for our full write up on Colgate’s earnings report!
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Image: Bigstock
Colgate (CL) Q2 Earnings In Line, Sales Miss, Stock Down
Colgate-Palmolive Company (CL - Free Report) , a global dealer in consumer goods, came out with second-quarter 2018 results. It recorded adjusted earnings of 77 cents per share, which came in line with the Zacks Consensus Estimate but grew 7% year over year.
For 2018, management envisions adjusted earnings per share to grow in mid-single-digit range on a year-over-year basis. However, GAAP earnings per share are expected to rise at double-digit rate.
Earnings Estimate Revision: The Zacks Consensus Estimate for 2018 has witnessed a downtrend in the last seven days. However, if we look at Colgate’s performance in the trailing four quarters (excluding the quarter under review), the company has outperformed the Zacks Consensus Estimate by an average of 0.3%.
Colgate-Palmolive Company Price, Consensus and EPS Surprise
Colgate-Palmolive Company Price, Consensus and EPS Surprise | Colgate-Palmolive Company Quote
Revenues: Colgate’s sales increased 1.5% to $3,886 million during the quarter, owing to 1.5% growth from volumes and 4.5%. Pricing remained flat with the prior-year period. Organic sales rose 0.5% in the quarter. However, sales came below the Zacks Consensus Estimate of $3,899 million.
Depending upon the current spot rates, management anticipates both net sales and organic sales to grow in low-single digits in 2018.
Zacks Rank: Currently, Colgate carries a Zacks Rank #4 (Sell), which is subject to change, based on the just released earnings results.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Stock Movement: Colgate’s shares dipped nearly 3.6% during pre-market trading hours following the earnings release.
Check back later for our full write up on Colgate’s earnings report!
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>